GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » PTC Therapeutics Inc (FRA:BH3) » Definitions » Cyclically Adjusted Revenue per Share

PTC Therapeutics (FRA:BH3) Cyclically Adjusted Revenue per Share : €8.55 (As of Mar. 2025)


View and export this data going back to 2013. Start your Free Trial

What is PTC Therapeutics Cyclically Adjusted Revenue per Share?

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

PTC Therapeutics's adjusted revenue per share for the three months ended in Mar. 2025 was €12.593. Add all the adjusted revenue per share for the past 10 years together and divide the count will get our Cyclically Adjusted Revenue per Share, which is €8.55 for the trailing ten years ended in Mar. 2025.

During the past 12 months, PTC Therapeutics's average Cyclically Adjusted Revenue Growth Rate was -100.00% per year. During the past 3 years, the average Cyclically Adjusted Revenue Growth Rate was 20.80% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted Revenue Growth Rate using Cyclically Adjusted Revenue per Share data.

During the past 13 years, the highest 3-Year average Cyclically Adjusted Revenue Growth Rate of PTC Therapeutics was 20.80% per year. The lowest was 20.80% per year. And the median was 20.80% per year.

As of today (2025-05-07), PTC Therapeutics's current stock price is €35.40. PTC Therapeutics's Cyclically Adjusted Revenue per Share for the quarter that ended in Mar. 2025 was €8.55. PTC Therapeutics's Cyclically Adjusted PS Ratio of today is 4.14.

During the past 13 years, the highest Cyclically Adjusted PS Ratio of PTC Therapeutics was 11.11. The lowest was 3.11. And the median was 7.14.


PTC Therapeutics Cyclically Adjusted Revenue per Share Historical Data

The historical data trend for PTC Therapeutics's Cyclically Adjusted Revenue per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

PTC Therapeutics Cyclically Adjusted Revenue per Share Chart

PTC Therapeutics Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Cyclically Adjusted Revenue per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only - 3.74 4.79 5.81 7.04

PTC Therapeutics Quarterly Data
Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25
Cyclically Adjusted Revenue per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 6.12 6.82 6.43 7.04 8.55

Competitive Comparison of PTC Therapeutics's Cyclically Adjusted Revenue per Share

For the Biotechnology subindustry, PTC Therapeutics's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


PTC Therapeutics's Cyclically Adjusted PS Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, PTC Therapeutics's Cyclically Adjusted PS Ratio distribution charts can be found below:

* The bar in red indicates where PTC Therapeutics's Cyclically Adjusted PS Ratio falls into.


;
;

PTC Therapeutics Cyclically Adjusted Revenue per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

What is Cyclically Adjusted Revenue per Share? How do we calculate Cyclically Adjusted Revenue per Share?

Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted Revenue per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the revenue per share from 2001 through 2010.

We adjusted the 2001 revenue per share data with the total inflation from 2001 through 2010 to the equivalent revenue in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's revenue is $1 a share in 2001, then the 2001's equivalent revenue in 2010 is $1.4 a share. If Wal-Mart's revenue is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 revenue in 2010 is $1.35. So on and so forth, you get the equivalent revenue per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted Revenue per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, PTC Therapeutics's adjusted Revenue per Share data for the three months ended in Mar. 2025 was:

Adj_RevenuePerShare= Revenue per Share /CPI of Mar. 2025 (Change)*Current CPI (Mar. 2025)
=12.593/134.9266*134.9266
=12.593

Current CPI (Mar. 2025) = 134.9266.

PTC Therapeutics Quarterly Data

Revenue per Share CPI Adj_RevenuePerShare
201506 0.180 100.684 0.241
201509 0.257 100.392 0.345
201512 0.345 99.792 0.466
201603 0.500 100.470 0.671
201606 0.409 101.688 0.543
201609 0.601 101.861 0.796
201612 0.699 101.863 0.926
201703 0.724 102.862 0.950
201706 1.077 103.349 1.406
201709 0.850 104.136 1.101
201712 1.591 104.011 2.064
201803 1.092 105.290 1.399
201806 1.275 106.317 1.618
201809 0.955 106.507 1.210
201812 1.507 105.998 1.918
201903 0.849 107.251 1.068
201906 1.354 108.070 1.690
201909 1.148 108.329 1.430
201912 1.399 108.420 1.741
202003 0.990 108.902 1.227
202006 1.025 108.767 1.272
202009 1.486 109.815 1.826
202012 1.418 109.897 1.741
202103 1.411 111.754 1.704
202106 1.375 114.631 1.618
202109 1.671 115.734 1.948
202112 2.069 117.630 2.373
202203 1.896 121.301 2.109
202206 2.194 125.017 2.368
202209 3.060 125.227 3.297
202212 2.175 125.222 2.344
202303 2.792 127.348 2.958
202306 2.641 128.729 2.768
202309 2.444 129.860 2.539
202312 3.730 129.419 3.889
202403 2.527 131.776 2.587
202406 2.261 132.554 2.301
202409 2.305 133.029 2.338
202412 2.636 133.157 2.671
202503 12.593 134.927 12.593

Add all the adjusted revenue per share together and divide 10 will get our Cyclically Adjusted Revenue per Share.


PTC Therapeutics  (FRA:BH3) Cyclically Adjusted Revenue per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted Revenue per Share may underestimate the company's revenue. Cyclically Adjusted PS Ratio can seem to be too high even the actual PS Ratio is low.

For the Cyclically Adjusted PS Ratio, the revenue per share of the past 10 years are inflation-adjusted and averaged. The result is used for P/S calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted PS Ratio is also called CAPS Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted revenue per share of a company over the past 10 years.

PTC Therapeutics's Cyclically Adjusted PS Ratio of today is calculated as

Cyclically Adjusted PS Ratio=Share Price/Cyclically Adjusted Revenue per Share
=35.40/8.55
=4.14

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

During the past 13 years, the highest Cyclically Adjusted PS Ratio of PTC Therapeutics was 11.11. The lowest was 3.11. And the median was 7.14.


Be Aware

Cyclically Adjusted PS Ratio works better for cyclical companies. It gives you a better idea on the company's real revenue value.


PTC Therapeutics Cyclically Adjusted Revenue per Share Related Terms

Thank you for viewing the detailed overview of PTC Therapeutics's Cyclically Adjusted Revenue per Share provided by GuruFocus.com. Please click on the following links to see related term pages.


PTC Therapeutics Business Description

Industry
Traded in Other Exchanges
Address
500 Warren Corporate Center Drive, Warren, NJ, USA, 07059
PTC Therapeutics Inc is a biopharmaceutical company that discovers, develops and commercializes clinically differentiated medicines that provide benefits to children and adults living with rare disorders. Its diversified therapeutic portfolio that includes several commercial products and product candidates in various stages of development, including discovery, research and clinical stages, focused on the development of new treatments for multiple therapeutic areas for rare diseases relating to neurology and metabolism. The Company views its operations and manages its business in one operating segment: life science.

PTC Therapeutics Headlines

No Headlines